Saturday, 7 November 2026European Markets

BUREAU VERITAS And IPSOS Have A High Dividend Yield And Return On Equity In The Consulting Services Industry.

Loading stream...

(vianews) - bureau veritas (bvi.pa) is among this list of stock assets with the highest dividend rate and return on equity on the consulting services industry.

financial asset price forward dividend yield return on equity
bureau veritas (bvi.pa) €24.62 3.22% 27.64%
ipsos (ips.pa) €45.04 2.95% 13.83%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. bureau veritas (bvi.pa)

3.22% forward dividend yield and 27.64% return on equity

bureau veritas sa provides laboratory testing, inspection, and certification services. it operates through six segments: marine & offshore; agri-food & commodities; industry; buildings & infrastructure; certification; and consumer products. the company engages in inspecting, analyzing, auditing, and certifying the products, assets, and management systems of its customers in relation to regulatory or self-imposed standards, as well as issues compliance reports. it also provides laboratory and on-site testing services for manufacturing and process industries; inspection services for products, services, assets, and installations, as well as various services designed to control quality, verify quantity, and meet regulatory requirements; and certification services for management systems, products, and people. the company serves automotive and transportation, building and infrastructure, chemicals, commodities and agriculture, consumer products and retail, food, marine and offshore, oil and gas, and power and utilities industries, as well as financial services and public sectors. it operates in approximately 140 countries through a network of 1,600 offices and laboratories. bureau veritas sa was founded in 1828 and is headquartered in neuilly-sur-seine, france.

earnings per share

as for profitability, bureau veritas has a trailing twelve months eps of €1.04.

pe ratio

bureau veritas has a trailing twelve months price to earnings ratio of 23.67. meaning, the purchaser of the share is investing €23.67 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 27.64%.

more news about bureau veritas.

2. ipsos (ips.pa)

2.95% forward dividend yield and 13.83% return on equity

ipsos sa, through its subsidiaries, provides survey-based research services for companies and institutions in europe, the middle east, africa, the americas, and the asia-pacific. the company offers services in the information production and analysis chain, including data collection, data processing and integration, data analysis, information delivery and presentation, and information activation. it also provides audience measurement, automotive and mobility development, brand health tracking, channel performance, corporate reputation, creative excellence, customer experience, healthcare, innovation, ipsos mma, ipsos uu, market strategy and understanding, observer, public affairs, social intelligence analytics, and other specialist services, as well as research methodologies, such as device agnosticism, programmatic sampling, and digital face-to-face interview. in addition, the company offers online and mobile integrated services and device agnostic solutions that include online surveys adapted to laptops, smartphones, and tablets; and qualitative research services, as well as operates ipsos.digital, a do-it-yourself platform. further, it provides artificial intelligence and data science solutions that develops and provides analytical tools based on data science, machine learning, big analytics, and modelling; and behavioral science and neuroscience solutions, as well as operates ipsos knowledge centre for teams and clients. ipsos sa was incorporated in 1975 and is headquartered in paris, france.

earnings per share

as for profitability, ipsos has a trailing twelve months eps of €4.12.

pe ratio

ipsos has a trailing twelve months price to earnings ratio of 10.93. meaning, the purchaser of the share is investing €10.93 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.83%.

volatility

ipsos's last week, last month's, and last quarter's current intraday variation average was a negative 0.19%, a positive 0.19%, and a positive 0.93%.

ipsos's highest amplitude of average volatility was 0.80% (last week), 0.68% (last month), and 0.93% (last quarter).

sales growth

ipsos's sales growth for the current quarter is negative 1.3%.

more news about ipsos.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com